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Abstract
Structural chromosomal changes including copy number aberrations (CNAs) are a major feature of multiple myeloma (MM),
however their evolution in context of modern biological therapy is not well characterized. To investigate acquisition of
CNAs and their prognostic relevance in context of first-line therapy, we profiled tumor diagnosis–relapse pairs from 178
NCRI Myeloma XI (ISRCTN49407852) trial patients using digital multiplex ligation-dependent probe amplification. CNA
profiles acquired at relapse differed substantially between MM subtypes: hyperdiploid (HRD) tumors evolved predominantly
in branching pattern vs. linear pattern in t(4;14) vs. stable pattern in t(11;14). CNA acquisition also differed between
subtypes based on CCND expression, with a marked enrichment of acquired del(17p) in CCND2 over CCND1 tumors.
Acquired CNAs were not influenced by high-dose melphalan or lenalidomide maintenance randomization. A branching
evolution pattern was significantly associated with inferior overall survival (OS; hazard ratio (HR) 2.61, P= 0.0048). As an
individual lesion, acquisition of gain(1q) at relapse was associated with shorter OS, independent of other risk markers or time
of relapse (HR= 2.00; P= 0.021). There is an increasing need for rational therapy sequencing in MM. Our data supports the
value of repeat molecular profiling to characterize disease evolution and inform management of MM relapse.
Introduction
Multiple myeloma (MM) is caused by the malignant clonal
expansion of plasma cells in the bone marrow [1].
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Approximately 40% of MM tumors harbor chromosome
t(4;14), t(11;14), or t(14;16)/t(14;20) translocations, which
result in overexpression of oncogenes (including WHSC1/
MMSET/NSD2, FGFR3, CCND1, MAF, and MAFB)
through juxtaposition to the immunoglobulin heavy-chain
locus [2, 3]. Other MM tumors exhibit hyperdiploidy
(HRD), which is considered an alternative initiating event.
Increased expression of CCND1 in t(11;14) and HRD and
increased CCND2 expression in t(4;14), t(14;16)/t(14;20),
and HRD are unifying downstream consequences of initi-
ating lesions [4–10].
Recent next-generation sequencing projects have pro-
vided insight into the sub-clonal complexity of tumor
progression in MM [11–14]. However, few recurrent single
nucleotide changes have been reported to be associated
with disease relapse, notably sub-clonal mutations of cer-
eblon in immunomodulatory drug (IMiD) treated patients.
Knowledge about their prognostic impact remains limited
[15]. In contrast, several large-scale chromosomal
abnormalities, including gain(1q), del(1p), and del(17p)
have been shown to be acquired during tumor progression,
but their association with tumor subtype, treatment and
outcome is not well understood [11, 16]. Recent studies of
the relationship between copy number aberrations (CNAs)
and progression of MM have largely been based on short-
read sequencing or FISH. Importantly, few studies have
been performed on patients from a randomized clinical trial
and the impact of therapy on acquisition of CNAs remains
unclear [15, 16]. To gain insight into the relationship
between CNAs and progression of MM we performed
virtual karyotyping of all chromosomes and targeted hot-
spot profiling using digital multiplexed ligation-dependent
probe amplification (digitalMLPA) in matched
diagnosis–relapse tumor pairs in 178 UK NCRI Myeloma
XI trial patients [17]. We show that acquisition of CNAs is
strongly correlated with MM subgroups. Additionally, a
number of acquired changes have independent predictive
value for defining patient outcome.
Material and methods
Patients
We studied 178 newly diagnosed MM patients enrolled in
UK NCRI Myeloma XI (ISRCTN49407852) for which high
quality bone marrow tumor material at both presentation
and relapse was available. First outcomes of the trial have
been published recently [17]. Briefly, patients were initially
randomized to triplet induction with thalidomide (CTD),
lenalidomide (CRD), or carfilzomib and lenalidomide
(KCRD; transplant-eligible patients only) in combination
with cyclophosphamide and dexamethasone. Insufficient
responders (partial or minimal response) were randomized
to cyclophosphamide, bortezomib and dexamethasone
(CVD) vs. no intensification and nonresponders (stable or
progressive disease) received CVD. Younger, fitter patients
received high-dose melphalan (HDMEL) and autologous
stem-cell transplantation, patients were randomized to
receive lenalidomide, lenalidomide plus vorinostat, or
observation. Maintenance treatment continued until pro-
gressive disease in the absence of toxicity (Supplementary
Fig. 1).
Median time to progression was 20.7 months (range
3.7–71.9 months) and median follow-up 47.0 months.
Baseline characteristics are summarized in Supplementary
Table 1. The frequency of chromosomal aberrations detect-
able in the 178 patients at presentation were representative of
the overall trial cohort (Supplementary Table 2) [4].
For all patients CD138-positive tumor cells were
immunomagnetically selected at presentation and relapse
and quality controlled for tumor cell purity (>95%), DNA
and RNA were extracted using QIAGEN (Hilden, Ger-
many) Allprep kits. Additional molecular quality control
including longitudinal consistency for IgD deletion status
was performed for all cases. Matched identity of
presentation-relapse pairs was confirmed using single
nucleotide and/or insertion/deletion polymorphisms assayed
by digitalMLPA D006-X2 for all samples.
All patients provided written informed consent. The
study was approved by the UK National Research Ethics
Service, research ethics committees at participating centers
and the UK Medicines and Healthcare Products Regulatory
Agency.
Translocation and copy number profiling
Multiplexed qRT-PCR was used to determine t(4;14),
t(6;14), t(11;14), t(14;16), and t(14;20) status in tumors,
based on the translocation cyclin D (TC) classification
system as previously described [5, 18].
Targeted genome wide CNA status at presentation and
relapse in each patient was assessed with a newly developed
research version of D006-X2 Multiple Myeloma digi-
talMLPA probemix, as previously described (Supplemen-
tary Methods) [19, 20]. Details of each probe and their
respective genomic positions are provided in Supplemen-
tary Table 3. CNAs involving sex chromosomes were not
considered. CNAs were called if ≥50% of probes mapping
to an individual gene or genomic region deviated from
normal diploid pattern.
Statistical analyses
Analyses were performed in R version 3.5.2 using
“dplyr”, “tidyr”, “stats”, “survival” and “survminer”,
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“ComplexHeatmap” and “ggpubr” packages. The associa-
tion between categorical variables was examined using
Fishers exact test and between continuous variables using
the Wilcoxon signed-rank test. Progression-free survival
(PFS) was defined as time from induction randomization to
progression, according to International Myeloma Working
Group criteria, or death of any cause. Overall survival (OS)
was time from induction randomization to death of any
cause. Cox proportional hazards (PH) regression was used
to estimate univariate and multivariable hazard ratios (HRs)
and 95% confidence intervals (CI). To examine the pre-
dictive value of evolution in CNA status for subsequent
therapy, high-risk CNA were considered as time dependent
covariates within the multivariate model. The PH assump-
tion was tested to investigate whether time dependent
covariate effects persisted irrespective of time of acquisition
(Supplementary Methods). Multivariate covariates included
t(4;14), t(14;16), del(1p), gain(1q), del(17p) and treatment
pathway (transplant eligible vs. not). This is relevant
because, although the median follow-up of this cohort is
long, the inherent requirement of a relapse biopsy excludes
the longest responders from our analyses as they are still on
active trial medication or observation with no evidence of
disease progression. Differences between Kaplan–Meier
survival curves was assessed using the log-rank test. A two-
sided P value of ≤0.05 was considered statistically
significant.
Results
Acquisition of new CNAs is a feature of relapse
Relapse was associated with the acquisition of new CNAs
in 87.1% of tumors, most (73.2%) being large-scale chro-
mosome changes. Across all patients, relapse was asso-
ciated with a higher number of CNAs: median 11.5 (range
0–34) vs. median 12 (range 0–29) (P= 0.0058). As pre-
viously well-documented [16, 21], IGH translocations were
clonal at presentation and their status did not change at
relapse.
The most frequent chromosomal changes associated with
relapse were gain or amplification of 1q (19%), del(13q)
(10%), gain or amplification of 11q (9%) and del(17p)/TP53
in (8%) (Fig. 1; Supplementary Table 2). Although not
common, some clonal CNAs detectable at presentation were
not detectable at relapse, in particular gain of odd numbered
chromosomes in HRD tumors (Supplementary Fig. 2).
Evolution of sub-chromosomal aberrations
In contrast to 1q gain, which generally involved the whole
chromosomal arm, clonal 1p deletions tended to be sub-
chromosomal (Fig. 1): 1p32.3 deletion (9/178; 5.1%)
implicating CDKN2C or 1p12 implicating FAM46C (4/178;















































































Fig. 1 Recurrent chromosomal and sub-chromosomal CNA
changes at relapse. A Frequency of CNAs emerging at relapse
affecting chromosome arms, including new gain (red), amplification
(yellow), heterozygous deletion (blue), or homozygous deletion
(green) plotted as a bar graph. B Bar graph showing frequency of 1q,
13q, and 17p CNAs, including gain (red), amplification (yellow),
heterozygous deletion (blue), or homozygous deletion (green), at
presentation and relapse. C Heat map of evolving chromosome 1
CNAs at relapse, 63 tumors with change in this region at relapse. On
the left (Y-axis) dendrogram representing unsupervised clustering
analysis of emerging CNAs in areas interrogated by digitalMLPA
probes, which are annotated with gene names and chromosomal
location below (X-axis). Change per probe and tumor color-coded as
per scale representing normalized digitalMLPA copy number ratios
with 1.0 equivalent to normal/diploid.
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at diagnosis, the deletion was not clonally detectable at
relapse; in contrast all but one of the 8 presentation 1p32.3
(CDKN2C) deletions were detectable at relapse.
Focal gain at relapse also affected 8q24.21, involving the
MYC locus, in 10/178 (5.6%) tumors. In three of 15 tumors
with MYC gain at presentation, reversion to diploid status
was a feature of relapse.
Sub-chromosomal CNAs involving IMiD response genes
—CRBN (3p26.2), IKZF1 (7p12.2), IKZF3 (17q12), and
IRF4 (6p25.3)—were infrequent (Supplementary Fig. 3).
Most were detectable in tumors relapsing off therapy (no
maintenance); only 2 out of 10 were a feature of tumors
from patients in receipt of lenalidomide maintenance
(1 deletion of CRBN; 1 gain IRF4).
Evolution of driver copy number aberrations
We next examined for clonal emergence at relapse of sub-
clonal changes at diagnosis, focusing on the most frequent
drivers—gain(1q) and del(17p). We and others showed
before that calling of CNAs using conservative high con-
fidence MLPA cutoff values detects clonal infiltration
equivalent to about >20% by FISH, but that calling of minor
sub clones is also feasible [4]. Thirty percent of patients’
tumors with clonally detectable 1q gain at relapse had a
detectable, potential minor sub-clonal gain(1q) at diagnosis
and 50% of del(17p) relapse tumors had potential sub-
clonal del(17p) at diagnosis (Supplementary Fig. 4). Pro-
gressive clonal expansion of 1q positive tumors was a
feature of 17.5% gain(1q) cases, whereby gain at diagnosis
evolved into tetraploidy of 1q (amp(1q)) at relapse. Two of
15 tumors with gain of MYC at diagnosis progressed to
amplification at relapse. This was also a feature with gain of
15q (4.4%) and 19p (2.3%), albeit at low frequency.
We and others have demonstrated that patients with
double or triple hit tumors (i.e., 2+ high-risk aberrations
t(4;14), t(14;16), t(14;20), gain(1q), or del(17p)) have an
especially poor prognosis [4]. It was noteworthy that some
tumors with 0 or 1 lesions progressed to carrying double,
triple and quadruple hits at relapse (Fig. 2). Amplification
1q has recently been proposed as an additional independent
marker of high risk by some researchers [22]. In our study
around two thirds of amp(1q) tumors were “double hit”, i.e.,
also carried t(4;14), t(14;16), t(14;20), or del(17p). Of all
178 relapsed tumors, nearly 10% carried both amp(1q) and
“double hit” genetic features (Fig. 2).
Impact of subtype on copy number profile
Given the biological heterogeneity of MM we examined the
relationship between CNAs and disease progression by
subtype: those with IG translocations (t(4;14), t(11;14),
t(14;16)/t(14;20)), and those with HRD, sub-grouped into
those with and without gain of 11, in analogy to Translo-
cation and Cyclin D (TC) classification (Supplementary
Table 2) [4, 5].
Emerging CNA patterns at relapse were classified as
branching (45.5% of all tumors), linear (22.5%), linear loss
(19.1%), and stable (12.9%) (Fig. 3). In HRD the majority
of tumors showed evidence of branching evolution (57.3%)
(Fig. 3). In contrast, linear evolution dominated (36.8%)
t(4;14) MM. t(11;14) tumors primarily showed either no
CNA change at relapse (stable; 33.3%), or linear evolution
(28.6%) (Fig. 3). Importantly, there was no relationship
between acquisition of CNAs and either HDMEL or lena-
lidomide maintenance therapy (Fig. 4).
Both del(13) (94.7%) and gain/amp (1q) (68.4%) were
seen at high frequency in t(4;14) MM at presentation, and
the CNAs were seen at even higher frequencies in relapse
tumors at 100% and 79.0%, respectively (Supplementary
Fig. 5). Moreover, at relapse del(17p) was a feature of
31.6% of t(4;14) tumors (Supplementary Fig. 5). In con-
trast, acquisition of 1q, 2p, 8q, 9p, 9q, or 6q CNAs, the
changes occurring in t(11;14), were not common; each of
these aberration was acquired in <5% of t(11;14) relapsed
tumors (Fig. 3). Due to their low frequency, as expected,
t(14;16) (two patients) and t(14;20) (one patient) tumors are
not discussed; sequential CNA analysis providing limited
information regarding subgroup evolutionary trajectory.
Baseline and relapse CNAs for t(14;16) and t(14;20) shown
in Supplementary Fig. 6.
Finally, we examined the relationship between CNA
change and MM subtypes defined by CCND expression;
CCND1 (D1), CCND2 (D2), or both (D1+D2) (Supple-
mentary Fig. 7). Acquisition of del(17p) was associated
primarily with D2 subtype (Supplementary Fig. 8). Speci-
fically, acquired del(17p) at relapse was a feature of 14.6%
of D2, 12.0% of D1+ 2, and 5.1% of D1 tumors. Overall,
acquisition of new lesions was less frequent in HRD with
gain(11), characterized by D1 expression, vs. other HRD
tumors (Supplementary Fig. 9).
Associations with patient outcome
Gain(1q) (HR= 2.23; P < 0.001), del(1p)/CDKN2C (HR=
1.81; P= 0.046), gain(8q)/MYC (HR= 1.87; P= 0.033),
and del(17p) (HR= 2.95; P < 0.001) considered as time
dependent variables, i.e., including their acquisition at
relapse, were all independently associated with shorter OS
(Table 1; Supplementary Fig. 10; Supplementary Table 4).
CNAs were stratified by time point of acquisition, i.e.,
“Gain-Gain” for those with stable gain and “Diploid-Gain”
for those with evolution of gain(1q) at relapse. Gain(1q)
from presentation and evolution of new gain(1q) at relapse
were both associated with significantly shorter OS com-
pared to normal 1q copy number (HR 2.11; P= 0.0040 and
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HR 2.00; P= 0.021, respectively). Median OS was 44.3 vs.
47.9 vs. 67.1 months for gain(1q) at diagnosis, new gain
(1q) at relapse and normal 1q copy number at both time
points, respectively (log-rank P= 0.007) (Fig. 5).
Acquired del(17p), del(1p/CDKN2C) or gain(8q/MYC) at
relapse were not clearly associated with a significantly
worse OS in subgroup analyses, although our power to
demonstrate a relationship was naturally limited by low
frequency of these CNAs. Median OS was 31.3 vs. 60.5 vs.
65.4 months for del(17p) at diagnosis, emergence at relapse
and absence at both, respectively (log-rank P < 0.001)
(Fig. 5). Median OS was 38.3 vs. 44.6 vs. 63.4 months for
del(1p/CDKN2C) at diagnosis, emergence at relapse or
absence, respectively (log-rank P= 0.03) (Fig. 5); and for
gain(8q/MYC), 38.3 vs. 36.2 vs. 63.4 months, respectively
(log-rank P= 0.07) (Fig. 5).
Of interest, type of evolutionary pattern was associated
with OS; branching evolution was significantly associated
with the shortest and linear loss with the longest OS (HR
2.61, P= 0.0048), with median OS being 44.6 vs. 59.6 vs.
62.0 vs. 68.1 months for branching, linear, no change and
linear loss respectively (log-rank P= 0.02) (Fig. 5).
Discussion
Our analysis demonstrates that progression of MM is
characterized by emergence of clones with additional large-
scale chromosomal changes, commonly involving 1q. Gain
or amp(1q) frequently co-evolves with other CNAs, either
implicating 1q directly in their genesis as per “jumping 1q”
hypothesis, or highlighting 1q as a region providing clonal
advantage for genetically instable tumors [23]. While a
number of genes on 1q have been proposed as drivers, our
study does not provide data to make a specific inference
[8, 24–27]. Our findings also suggest progression of MM is
associated with positive selection of sub-chromosomal
loss of 1p, implicating CDKN2C, and thereby indirectly


















































































































Co−occurrence of Amp(1q) with HR lesions
A) C)
B)
Fig. 2 Positive selection of co-occurrence of high-risk lesions.
A Frequency bar chart of tumors characterized by number of high-risk
markers, ranging from no (0) high-risk marker to co-occurrence of 4
markers. B Upset plots of Presentation (left) and Relapse (right)
tumors, each showing frequency of individual high-risk lesions (left),
type of combination of lesions (center lines with dots indicating
presence of individual lesion) and frequency of specific combination of
markers (top). C Bar chart showing the overall frequency of amp(1q)
between presentation and relapse (overall bar height) and proportion of
amp(1q) tumors showing 1q as the only high-risk aberration (single
hit), or in combination with one or more other high-risk markers
(double hit to quadruple hit).
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CDK4/6 in conferring clonal survival benefit at progression.
We also identified recurrent sub-chromosomal gain at
relapse of an area to which MYC maps (chr8q24.21), in line
with its driver role in B-cell malignancies [28, 29].
By considering MM molecular subtype, we highlight
differences in evolution trajectories, particularly between
HRD and IG translocated MM, but also between t(4;14) and
t(11;14) and/or between CCND2 and CCND1 driven tumors
[5]. Of note, there is a marked enrichment of acquisition of
del(17p) at relapse in CCND2 driven tumors which has, to
our knowledge, not been described before. These differ-
ences are features of subtypes irrespective of therapy. Our
findings are in keeping with published observations for
evolution of pre-therapeutic mutational patterns but extend
these in context of therapy and relapse [30–32]. We also
describe, to our knowledge for the first time, an association
between CNA evolution pattern and subsequent outcome.
Whether individual CNA evolution pattern has independent
clinical relevance and could be included in management
considerations at relapse requires further investigation.
We identified only a low frequency of CNAs to which
IMiD response genes map. In conjuncture with published
somatic SNV data, results suggest mutation of these genes
per se is not the major determinant of acquired resistance to
lenalidomide, or other members of this class of agent in










































































































B)          C)
Fig. 3 Relationship between CNAs at presentation and relapse and
MM subtype. A Co-occurrence in evolution of novel CNAs at relapse
in context of pathogenetic lesions (legend left side; dark bar= present,
gray= absent; legend bottom: black and white bands representing
chromosomal mapping of digitalMLPA probes chr1-22 from left to
right in ascending order of genomic position) displayed in a heat map
with unsupervised clustering for evolving CNAs. B Frequency of
evolutionary patterns across all tumors. C Frequency of evolutionary
patterns per major molecular MM subgroups.
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We demonstrate, to our knowledge for the first time, in a
randomized controlled trial that acquisition of gain(1q) at
relapse is independently and strongly associated with
inferior OS [36]. Although findings are also indicative for
del(17p), del(1p/CDKN2C) and gain(8q/MYC), our power
to robustly assert clinical relevance of acquired lesions at
relapse is inevitably limited by the lower frequency of these
CNAs [37]. Clinical evaluation of these markers at relapse
is technically feasible in most developed healthcare sys-
tems, but currently not widely recommended [38–40].
It is unknown whether sub-clones residing outside of the
standard iliac crest bone marrow sampling area at diagnosis
are the main source of clonal evolution detected at relapse
or whether these predominantly emerge through ongoing
genomic instability [12]. Multi-region bone sampling in
MM is associated with significant risk and morbidity,
making its implementation as part of standard care very
challenging. Functional bone marrow soft tissue imaging
techniques such as diffusion-weighted whole body MRI
and/or molecular techniques including circulating tumor
DNA profiling are promising methods in development
which may contribute to diagnostic assessment of spatial
MM heterogeneity in the future. However, sensitivity, pre-
cision and clinical relevance of minor sub-clone detection
from a single time point for these methods remains to be
established, in particular if results differ from those of
parallel bone marrow sampling, before informing clinical
management [41–44].
All patients received uniform trial treatment, in particular
providing insight into thalidomide and lenalidomide asso-
ciated CNA changes. However, patients also received low-
doses of the oral alkylator cyclophosphamide during
induction, which may have specific impact on CNA chan-
ges, potentially limiting generalizability of our findings.
In addition, molecular information generated with a tar-
geted tool like digitalMLPA is inherently focused and does
not discriminate complex processes potentially underlying
identified CNAs, such as chromotripsis or chromoplexy,
which are detectable by discovery tools such as whole gen-
ome sequencing, or single nucleotide variants captured by
myeloma specific CNA/sequencing panels [29, 45–47]. Our
data also cannot reflect accompanying changes of the tumor
microenvironment, which have been implicated in myeloma
progression [48]. However, digitalMLPA is in development












































































Fig. 4 Evolutionary patterns in context of trial treatment.
A Comparison of frequencies of evolutionary patterns between
transplant eligible (TE; younger, fitter patients) and transplant non
eligible (TNE). B Comparison of frequencies of evolutionary patterns
for patients randomized to lenalidomide (L) maintenance, observation
(O) or those not randomized (NR) (C) Heatmaps of CNA changes at
relapse for tumors from patients randomized to lenalidomide (L)
maintenance, observation (O) or those not randomized (NR). For each
group separately unsupervised clustering on CNA changes was per-
formed and a dendrogram is shown on the left of each heat map.
Legend on left side provides context on molecular background lesions
(dark bar= present, gray= absent). Legend at bottom: black and white
bands representing chromosomal mapping of digitalMLPA probes
chr1-22 from left to right in ascending order of genomic position.
Table 1 Multivariate Cox regression analysis of risk factors for OS,
where CNAs represent time dependent covariates.
HR 95% CI P value
t(4;14) 1.25 (0.62–2.54) 0.53
t(14;16) 1.75 (0.66–4.60) 0.26
Gain(1q) 2.23 (1.39–3.57) 0.0008
Del(1p)/CDKN2C 1.81 (1.01–2.26) 0.046
Gain(8q)/MYC 1.87 (1.05–3.31) 0.033
Del(17p) 2.95 (1.67–5.20) 0.0001
TNE 2.30 (1.41–3.75) 0.0008
HR hazard ratio, 95% CI 95% confidence interval.
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A)     B)
C)    D)
E)
Fig. 5 Relationship between emerging CNAs, evolutionary trajec-
tories, and patient outcome. A Kaplan–Meier plot for overall sur-
vival in context of presence of CNAs for 1q. Equivalent plots for
aberrations of (B) deletion of 1p21 (CDKN2C) (C) gain of 8q21
(MYC) (D) deletion of 17p (TP53) (E) evolutionary pattern. As per
individual color-coded label for A–D, curves represent patients with
tumors remaining diploid at both time points, changing from diploid to
abnormal or showing abnormality at both time points.
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information specific to myeloma from low tumor DNA
quantities at high throughput. It requires limited computa-
tional infrastructure and uses standardized analysis algo-
rithms, thus overcoming the significant limitations of
conventional FISH analysis [20]. As our study demonstrates,
digitalMLPA is suitable for longitudinal intra-individual
tracking and provides a standardized and accessible method
for cross-study validation and putative implementation in
molecularly stratified prospective clinical trials.
Genetic re-profiling at relapse in MM is currently not
widely recommended and, as a consequence, often not
reimbursed [10, 39, 49]. Whilst treatment options for
relapsed disease were until recently very limited, a range of
therapeutic regimens with varying intensity are now
approved and available, requiring better tools for clinical
decision making at relapse [50–53]. Adapting first-line
therapy and its intensity to individual tumor risk markers in
MM is now a key focus of research, with multiple geneti-
cally stratified prospective clinical trials currently ongoing
[10, 54, 55]. The debate about optimal tailoring of second
line treatment is likely to intensify with increasing ther-
apeutic options. Our study demonstrates not only the fre-
quency of emerging high-risk CNAs at MM relapse, but
also the unmet clinical need of patients with chromosomally
evolving MM. These patients should ideally be recognized
early during relapse and prospective clinical trials investi-
gating longitudinal management strategies adapted to
dynamic risk profiling, designed [56].
Our findings strongly support repeated tumor molecular
analysis in MM in context of modern treatment, even in
circumstances where only selected markers such as 1q can
be tested, as a means of tailoring patient treatment beyond
first-line therapy.
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